scholarly journals Reply to comment on: “Pattern hair loss: Assessment of microinflammation in miniaturized and terminal hair follicles through horizontal histologic sections”

2020 ◽  
Vol 83 (2) ◽  
pp. e147
Author(s):  
Manuel Valdebran ◽  
Joshua Mo ◽  
Linda Doan ◽  
Dirk M. Elston
2019 ◽  
Vol 14 (1) ◽  
pp. 66-71 ◽  
Author(s):  
Tiziana Prochilo ◽  
Alessandra Huscher ◽  
Federica Andreis ◽  
Mara Mirandola ◽  
Elisabetta Zaina ◽  
...  

Background: The most effective agents in the treatment of breast cancer have a common side effect, the hair loss. Some studies reported a reduction of hair loss with the use of the scalp cooling device. Indeed, it decreases the drug accumulation in the hair follicles. We report our preliminary experience with a scalp cooling device in reducing chemotherapy-induced alopecia and related distress in breast cancer patients undergoing adjuvant chemotherapy. </P><P> Methods: Hair loss grading and treatment tolerability were evaluated during chemotherapy every 21 days and 3 weeks after the last cycle of chemotherapy via Dean’s scale by patients and operators and a comfort analogic scale by patients. We administered the Hospital Anxiety and Depression Scale questionnaire at the baseline and at the end of treatment to assess the distress related to chemotherapy- induced alopecia. Results: Among the 46 patients identified, 27 accepted the device. The eligible chemotherapy regimens included docetaxel+cyclophosphamide (TC), doxorubicin+cyclophosphamide (AC) and paclitaxel (P) weekly+trastuzumab (T). 24 pts (89%) completed the treatment; 3 pts (11%) treated with AC prematurely interrupted use of the scalp-cooling device due to inefficacy. After the last cycle of chemotherapy, the number of patient who perceived a HL < grade 2 was 16 (59%). The hair retention reported by operators has been higher (78%). 81.5% of patients well tolerated the treatment. Conclusion: In our study, the scalp-cooling device reduced chemotherapy-induced alopecia in taxane- based chemotherapy. Furthermore, it suggests a discordance in hair loss perception between patients and operators.


Nutrients ◽  
2018 ◽  
Vol 10 (11) ◽  
pp. 1808 ◽  
Author(s):  
Gennaro Riccio ◽  
Eduardo Sommella ◽  
Nadia Badolati ◽  
Emanuela Salviati ◽  
Sara Bottone ◽  
...  

Chemotherapy-induced alopecia (CIA) is a common side effect of conventional chemotherapy and represents a major problem in clinical oncology. Even months after the end of chemotherapy, many cancer patients complain of hair loss, a condition that is psychologically difficult to manage. CIA disturbs social and sexual interactions and causes anxiety and depression. Synthetic drugs protecting from CIA and endowed with hair growth stimulatory properties are prescribed with caution by oncologists. Hormones, growth factors, morphogens could unwontedly protect tumour cells or induce cancer cell proliferation and are thus considered incompatible with many chemotherapy regimens. Nutraceuticals, on the contrary, have been shown to be safe and effective treatment options for hair loss. We here show that polyphenols from Malus Pumila Miller cv Annurca are endowed with hair growth promoting activity and can be considered a safe alternative to avoid CIA. In vitro, Annurca Apple Polyphenolic Extract (AAE) protects murine Hair Follicles (HF) from taxanes induced dystrophy. Moreover, in virtue of its mechanism of action, AAE is herein proven to be compatible with chemotherapy regimens. AAE forces HFs to produce ATP using mitochondrial β-oxidation, reducing Pentose Phosphate Pathway (PPP) rate and nucleotides production. As consequence, DNA replication and mitosis are not stimulated, while a pool of free amino acids usually involved in catabolic reactions are spared for keratin production. Moreover, measuring the effect exerted on Poly Unsaturated Fatty Acid (PUFA) metabolism, we prove that AAE promotes hair-growth by increasing the intracellular levels of Prostaglandins F2α (PGF2α) and by hijacking PUFA catabolites toward β-oxidation.


2013 ◽  
Author(s):  
James Q Del Rosso

A basic knowledge of the hair growth cycle is needed to evaluate disorders of hair growth. This chapter presents a broad overview of the physiology and evaluation of hair growth, as well as discussions of specific types of alopecia. The epidemiology, pathogenesis, diagnosis, and treatment of androgenetic alopecia, the most common type of nonscarring hair loss, are covered. Diffuse hair shedding is generalized hair loss over the entire scalp. Diagnosis and treatment of telogen effluvium, anagen arrest (anagen effluvium), and other causes of diffuse hair shedding are covered in detail. Alopecia areata, typically characterized by patchy hair loss; cicatricial alopecia, which results from permanent scarring of the hair follicles; and miscellaneous causes of hair loss are also discussed. Tables list the causes of diffuse and cicatricial alopecia, telogen effluvium, and miscellaneous chemicals and categories of drugs that can cause alopecia, as well as miscellaneous causes of hair loss. Included is an algorithm outlining the approach to diagnosing nonscarring alopecia, as well as a variety of clinical photographs. This review contains 9 highly rendered figures, 6 tables, and 42 references.


2021 ◽  
Vol 14 (3) ◽  
pp. e240579
Author(s):  
Katherine Leigh Hull ◽  
Richard Gooding ◽  
James O Burton

Warfarin is frequently prescribed as a long-term anticoagulant in patients with end-stage kidney disease as direct oral anticoagulants undergo renal excretion. Anticoagulation is a rare cause of alopecia in adults and is thought to be due to the promotion of the ‘resting phase’ of hair follicles. In this case report, a prevalent haemodialysis female patient required long-term anticoagulation following a complex pulmonary embolus and dialysis access complications. After commencing warfarin therapy, the patient reported generalised loss and thinning of her hair. All other potential causes were excluded. Cessation of warfarin therapy and conversion to apixaban with close monitoring alleviated the hair loss. Warfarin therapy is a rare cause of alopecia but should be considered in patients on long-term anticoagulation when other diagnoses have been excluded. Hair loss has a profoundly negative impact on patient quality of life and should prompt investigation to determine the underlying cause.


2017 ◽  
Vol 4 (7) ◽  
pp. 58-58 ◽  
Author(s):  
Pietro Gentile ◽  
Maria G. Scioli ◽  
Alessandra Bielli ◽  
Augusto Orlandi ◽  
Valerio Cervelli

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Eun Young Lee ◽  
You Jin Nam ◽  
Sangjin Kang ◽  
Eun Ju Choi ◽  
Inbo Han ◽  
...  

Abstract Background Stress is an important cause of skin disease, including hair loss. The hormonal response to stress is due to the HPA axis, which comprises hormones such as corticotropin releasing factor (CRF), adrenocorticotropic hormone (ACTH), and cortisol. Many reports have shown that CRF, a crucial stress hormone, inhibits hair growth and induces hair loss. However, the underlying mechanisms are still unclear. The aim of this study was to examine the effect of CRF on human dermal papilla cells (DPCs) as well as hair follicles and to investigate whether the HPA axis was established in cultured human DPCs. Results CRF inhibited hair shaft elongation and induced early catagen transition in human hair follicles. Hair follicle cells, both human DPCs and human ORSCs, expressed CRF and its receptors and responded to CRF. CRF inhibited the proliferation of human DPCs through cell cycle arrest at G2/M phase and induced the accumulation of reactive oxygen species (ROS). Anagen-related cytokine levels were downregulated in CRF-treated human DPCs. Interestingly, increases in proopiomelanocortin (POMC), ACTH, and cortisol were induced by CRF in human DPCs, and antagonists for the CRF receptor blocked the effects of this hormone. Conclusion The results of this study showed that stress can cause hair loss by acting through stress hormones. Additionally, these results suggested that a fully functional HPA axis exists in human DPCs and that CRF directly affects human DPCs as well as human hair follicles under stress conditions.


2021 ◽  
pp. 1373-1378
Author(s):  
Nagham Darhouse

Hair restoration focuses on replacing hair where it has been lost, although there is also a demand for hair to be placed where it is desired, but lacking, for a perceived aesthetic gain. For both men and women, hair loss can be devastating and lead to loss of confidence and self-esteem. Hair restoration can be beneficial but treatment should be tailored to the individual’s needs and the correct diagnosis for the hair loss needs to be determined through a detailed history, thorough examination, and appropriate investigations. The average human has over 5 million hair follicles of which only about 100,000 are located on the scalp. While it is loss of scalp hair that is often most noticeable and distressing, eyebrow and eyelash hair loss is also very obvious in both sexes, as is loss of beard and moustache hair in men. Hair loss may be localized or generalized, part of a medical condition, a side effect of medications, the result of a dermatological condition, or genetically predetermined. Hair restoration can be achieved through medical treatment, surgery, and non-surgical alternatives.


2018 ◽  
Vol 3 (10) ◽  
Author(s):  
Alexa Green ◽  
Felicia Jefferson

Everyone wants shine, softness, and hair strength, all key factors in having healthy hair. The purpose of this literature review is to provide information about healthy hair growth. Research states that the hair grows from follicles within the skin. Hair follicles are sacs where hair grows and where the sebaceous glands open. The follicles lined by cells derived from the epidermal. Keratin protects epithelial cells from damage and it makes up the outer layer of human skin. Even though there are many ways you can grow your hair, there are many ways you can lose your hair as well. This review paper also explains disorders that can cause hair loss.


Sign in / Sign up

Export Citation Format

Share Document